Intriguingly, transcriptomic analyses revealed dynamic PPARγ expression during NAFLD progression—compensatory upregulation in early stages and downregulation in advanced disease—highlighting the need for novel modulators. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.